OncoMed Pharmaceuticals, Inc. (OMED) Financial Statements (2024 and earlier)

Company Profile

Business Address 800 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:70,90079,90088,400103,100113,600129,800
Cash and cash equivalents8,40610,56114,12513,27715,87731,940
Short-term investments62,45069,30574,29989,81497,71097,828
Other undisclosed cash, cash equivalents, and short-term investments4434(24)91332
Asset, held-for-sale, not part of disposal group      
Other undisclosed current assets2,2851,5691,9512,1052,7655,178
Total current assets:73,18581,46990,351105,205116,365134,978
Noncurrent Assets
Property, plant and equipment2,3622,5322,9343,2753,3683,783
Other noncurrent assets1,6061,9081,8461,842748584
Total noncurrent assets:3,9684,4404,7805,1174,1164,367
TOTAL ASSETS:77,15385,90995,131110,322120,481139,345
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,7344,7433,6606,5055,4137,251
Accounts payable3,1639817042,5657792,115
Accrued liabilities4,5713,7622,9563,9404,6345,136
Deferred rent credit   
Restructuring reserve  5537300300
Deferred revenue and credits27,91982,19320,05320,053
Contract with customer, liability11,27825,908 
Other undisclosed current liabilities2,3272,5703,2814,3978,58012,258
Total current liabilities:21,33933,22634,86593,13234,34639,862
Noncurrent Liabilities
Liabilities, other than long-term debt4,0908,70813,93465,793148,290153,270
Deferred revenue and credits13,54865,410147,912152,895
Accounts payable and accrued liabilities   386383378375
Contract with customer, liability  4,888 
Deferred rent credit4,0903,820 
Other liabilities      
Total noncurrent liabilities:4,0908,70813,93465,793148,290153,270
Total liabilities:25,42941,93448,799158,925182,636193,132
Equity
Equity, attributable to parent51,72443,97546,332(48,603)(62,155)(53,787)
Common stock383838383837
Additional paid in capital408,868407,229405,397403,077399,102396,683
Accumulated other comprehensive income (loss)(62)(57)156289175272
Accumulated deficit(357,120)(363,235)(359,259)(452,007)(461,470)(450,779)
Total equity:51,72443,97546,332(48,603)(62,155)(53,787)
TOTAL LIABILITIES AND EQUITY:77,15385,90995,131110,322120,481139,345

Income Statement (P&L) ($ in thousands)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
Revenues19,5186,8707,84920,6395,1066,195
Revenue, net7,84920,6395,1066,195
Gross profit:19,5186,8707,84920,6395,1066,195
Operating expenses(13,727)(11,758)(13,781)(12,394)(16,131)(21,630)
Operating income (loss):5,791(4,888)(5,932)8,245(11,025)(15,435)
Income (loss) from continuing operations before equity method investments, income taxes:5,791(4,888)(5,932)8,245(11,025)(15,435)
Other undisclosed income from continuing operations before income taxes324524363123337214
Income (loss) from continuing operations before income taxes:6,115(4,364)(5,569)8,368(10,688)(15,221)
Income tax expense (benefit) 388(5)1,095(4)(4)
Income (loss) from continuing operations:6,115(3,976)(5,574)9,463(10,692)(15,225)
Income (loss) before gain (loss) on sale of properties:6,115(3,976)(5,574)9,463(10,692)(15,225)
Net income (loss) available to common stockholders, diluted:6,115(3,976)(5,574)9,463(10,692)(15,225)

Comprehensive Income ($ in thousands)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
Net income (loss):6,115(3,976)(5,574)9,463(10,692)(15,225)
Comprehensive income (loss):6,115(3,976)(5,574)9,463(10,692)(15,225)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(5)(213)(133)114(97)4
Comprehensive income (loss), net of tax, attributable to parent:6,110(4,189)(5,707)9,577(10,789)(15,221)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: